Portal de Periódicos da CAPES

Bacopa monniera extract reduces amyloid levels in PSAPP mice

2006; IOS Press; Volume: 9; Issue: 3 Linguagem: Inglês

10.3233/jad-2006-9303

1875-8908

Leigh A. Holcomb, Muralikrishnan Dhanasekaran, Angie R. Hitt, Keith A. Young, Mark W. Riggs, Bala V. Manyam,

Cholinesterase and Neurodegenerative Diseases

PSAPP mice expressing the "Swedish" amyloid precursor protein and M146L presenilin-1 mutations are a well-characterized model for spontaneous amyloid plaque formation. Bacopa monniera has a long history of use in India as an anti-aging and memory-enhancing ethnobotanical therapy. To evaluate the effect of Bacopa monniera extract (BME) on amyloid (Abeta) pathology in PSAPP mice, two doses of BME (40 or 160 mg/kg/day) were administered starting at 2 months of age for either 2 or 8 months. Our present data suggests that BME lowers Abeta 1-40 and 1-42 levels in cortex by as much as 60%, and reverses Y-maze performance and open field hyperlocomotion behavioral changes present in PSAPP mice. The areas encompassed by Congo Red-positive fibrillar amyloid deposits, however, were not altered by BME treatment. The data suggest that BME has potential application in Alzheimer's disease therapeutics.